RANKL is a key factor that is required for osteoclast differentiation and activation.[9] Some studies involving OS animal models[10] have shown that anti-RANKL agents can effectively decrease tumor growth, improve survival and inhibit lung metastasis. The gene discussed is TNFSF11; the disease is neoplasm.